Endonovo Therapeutics (ENDV) Stock Price, News & Analysis

Company Overview

Endonovo Therapeutics is a clinical‐stage biomedical company focused on developing non‐invasive therapeutic devices designed to modulate the immune system and promote tissue repair. The company’s proprietary Modulated Electrostatic Field (MEF) technology delivers pulsed energy to target inflammatory pathways and support cellular regeneration. Endonovo is primarily engaged in research and development aimed at treating conditions such as traumatic brain injury, hemorrhagic shock and acute inflammatory responses that currently have limited pharmaceutical options.

At the core of Endonovo’s platform is a portfolio of portable devices that generate precisely calibrated electrostatic fields to influence cellular behavior and accelerate the body’s natural healing processes. Preclinical studies have demonstrated the company’s technology can reduce levels of proinflammatory cytokines, improve microvascular flow and enhance tissue viability following injury. Endonovo’s research pipeline encompasses multiple device configurations, each tailored to specific indications including central nervous system trauma and systemic shock scenarios.

Operating as a US‐based medical technology developer, Endonovo Therapeutics maintains partnerships with academic institutions and contract research organizations to advance its clinical programs. While its headquarters and R&D activities are concentrated in North America, the company is exploring regulatory pathways overseas to extend its market reach. As it progresses toward human trials, Endonovo continues to strengthen its intellectual property portfolio, positioning its MEF platform for broader application across critical care and emergency medicine settings.

Key Stats

• Today's Range: $0.0001 to $0.0001
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.0003
• Volume: 8.00 million shs
• Average Volume: 553,337 shs
• Market Capitalization: $144.57 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ENDV Stock Analysis - Frequently Asked Questions

How have ENDV shares performed this year?

Endonovo Therapeutics' stock was trading at $0.0001 at the beginning of the year. Since then, ENDV shares have increased by 0.0% and is now trading at $0.0001.

How do I buy shares of Endonovo Therapeutics?

Shares of ENDV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Endonovo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Endonovo Therapeutics investors own include Chesapeake Energy (CHKAQ), Novavax (NVAX), Energous (WATT), Advanced Micro Devices (AMD), BioLineRx (BLRX), Citigroup (C) and Ekso Bionics (EKSO).

Company Calendar

• Today: 5/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:ENDV
• CIK: 1528172
• Web: www.endonovo.com
• Phone: (800) 489-4774
• Fax: 818-230-9899
• Employees: 1
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 14.46
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,445,710,000
• Free Float: 1,364,609,000
• Market Cap: $144.57 thousand
• Optionable: Not Optionable
• Beta: -1.05